ACTRN12620001012965招募中未知
Australian Myelodysplastic Syndromes (MDS) Patient Registry
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Patients with a new diagnosis of MDS confirmed on bone marrow biopsy.
- •This will include new diagnosis within 12 months prior to HREC approval at the site.
- •Or, cause of death listed as MDS within 12 months prior to HREC approval at the site.
排除标准
- •Patients who have chosen to ‘opt-out’ of the Registry.
研究者
相似试验
未知
不适用
Registration Program for Myelodysplastic Syndromes and Aplastic AnemiaJPRN-UMIN000000694Keio University School of Medicine50
进行中（未招募）
1 期
Darbepoetin alfa in Anaemic Subjects With Low Risk Myelodysplastic Syndromes - Companion Studyow or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)MedDRA version: 16.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851EUCTR2013-000727-13-BEAmgen Inc
招募中
1 期
Advancing treatment therapies in MyelodysplasiaMyelodysplasiaCancer - Leukaemia - Acute leukaemiaACTRN12622000410752Australasian Leukaemia and Lymphoma Group (ALLG)1,000
已完成
不适用
EWOG - MDS 98 Myelodysplastic Syndromes in ChildhoodProspective Study of the Diagnosis and Treatmentof Myelodysplastic Syndromes (MDS) in Childhood - EWOG-MDS 98Myelodysplastic syndrome, unspecifiedD46.9DRKS00000001niversitätsklinikum Freiburg714
进行中（未招募）
3 期
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic SyndromeMyelodysplastic Syndrome (MDS)NCT04401748AbbVie531